BCMA soluble form restores apoptotic death in B-CLL cells
. | Patients . | . | . | . | . | . | . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | 8B . | 10B . | 15C . | 19 . | 20 . | 21 . | Mean . | |||||
| Control | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |||||
| BCMA-Fc | 1.93 | 1.59 | 3.97 | 1.24 | 4.25 | 1.3 | 2.38* | |||||
| BCMA-Fc + BAFF | 1.74 | 1.94 | 4.16 | 0.3 | 1.83 | 1.41 | 1.9 | |||||
| BCMA-Fc + APRIL | 1.49 | 0.92 | 0.59 | 0.15 | 2.1 | 0.87 | 1.02† | |||||
. | Patients . | . | . | . | . | . | . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | 8B . | 10B . | 15C . | 19 . | 20 . | 21 . | Mean . | |||||
| Control | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |||||
| BCMA-Fc | 1.93 | 1.59 | 3.97 | 1.24 | 4.25 | 1.3 | 2.38* | |||||
| BCMA-Fc + BAFF | 1.74 | 1.94 | 4.16 | 0.3 | 1.83 | 1.41 | 1.9 | |||||
| BCMA-Fc + APRIL | 1.49 | 0.92 | 0.59 | 0.15 | 2.1 | 0.87 | 1.02† | |||||
Leukemic B cells from 6 B-CLL patients were cultured for 72 hours in the presence of 50 μg/mL BCMA-Fc alone or with 0.25 μg/mL soluble BAFF or APRIL. Results are expressed as the cytoplasm nucleosome enrichment in comparison with untreated cells taken as 1.
Probability (.01 ≤ P < .05) is expressed in comparison with untreated (*) or BCMA-Fc—treated (†) cells.